Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-masked, Pilot Study of the Safety and Efficacy of 0.5 µg/Day and 0.2 µg/Day Iluvien (Fluocinolone Acetonide Intravitreal Insert) 0.19 mg in Subjects With Macular Oedema Secondary to Retinal Vein Occlusion

Trial Profile

A Randomized, Double-masked, Pilot Study of the Safety and Efficacy of 0.5 µg/Day and 0.2 µg/Day Iluvien (Fluocinolone Acetonide Intravitreal Insert) 0.19 mg in Subjects With Macular Oedema Secondary to Retinal Vein Occlusion

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fluocinolone acetonide (Primary)
  • Indications Branch retinal vein occlusion; Central retinal vein occlusion; Retinal oedema
  • Focus Therapeutic Use
  • Acronyms FAVOR
  • Sponsors Alimera Sciences
  • Most Recent Events

    • 27 May 2015 Status changed from active, no longer recruiting to discontinued as per ClinicalTrials.gov.
    • 16 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top